Jeffrey Rothfeld, MD
Clinical Cardiac Electrophysiology · Bradenton, FLNPI 1811973001
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (53.8%), food and beverage and education — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 75.9% of it on its own, with 24 other manufacturers making up the rest. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in FL, where the typical reported total is $25,729.
Across 104 payments — averaging $55.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- Biosense Webster, Inc.$229
- Sanofi-aventis U.S. LLC$190
- Alnylam Pharmaceuticals Inc.$173
- Abbott$114
- Novartis$80
- plus $597 from 19 others
Across 57 payments — averaging $809.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$26K
- Boston Scientific$20K
What the payments were for
- Travel & lodging$3,09454%
- Food & beverage$2,63646%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 46 | $4,365 |
| Biosense Webster, Inc. | 10 | $229 |
| Sanofi-aventis U.S. LLC | 9 | $190 |
| Alnylam Pharmaceuticals Inc. | 2 | $173 |
| Abbott | 1 | $114 |
| Novartis | 4 | $80 |
| Boehringer Ingelheim | 1 | $76 |
| Novo Nordisk | 3 | $60 |
| Inari Medical, Inc. | 2 | $49 |
| Cardinal Health 200 LLC | 3 | $43 |
| Johnson & Johnson | 2 | $40 |
| Pfizer | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $35 |
| Philips North America LLC | 1 | $33 |
| Amgen | 2 | $31 |
| Cardiovascular Systems Inc. | 2 | $28 |
| Merck | 2 | $28 |
| AstraZeneca | 2 | $25 |
| Innovation Technologies Inc | 1 | $25 |
| Bardy Diagnostics, Inc. | 2 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| G Medical Diagnostic Services, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,749 in reported general payments places this provider in the 15th percentile of 249 clinical cardiac electrophysiology providers in Florida.
See all clinical cardiac electrophysiology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 627 | $696,178 |
| XareltoRivaroxaban | 312 | $344,981 |
| Repatha SureclickEvolocumab | 213 | $215,461 |
| EntrestoSacubitril/Valsartan | 174 | $212,263 |
| MultaqDronedarone Hcl | 114 | $156,260 |
| JardianceEmpagliflozin | 58 | $57,323 |
| Praluent PenAlirocumab | 31 | $33,287 |
| Flecainide Acetate | 318 | $14,980 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 53 | $13,846 |
| VascepaIcosapent Ethyl | 20 | $10,379 |
| Ezetimibe | 444 | $9,907 |
| Rosuvastatin Calcium | 743 | $8,475 |
| Metoprolol Succinate | 628 | $7,938 |
| Midodrine Hcl | 61 | $7,445 |
| Atorvastatin Calcium | 758 | $6,955 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $36 | $696,178627 claims |
| Johnson & JohnsonXarelto | $40 | $344,981312 claims |
| NovartisEntresto | $80 | $212,263174 claims |
| Sanofi-aventis U.S. LLCMultaq | $190 | $156,260114 claims |
| Boehringer IngelheimJardiance | $76 | $57,32358 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 249 clinical cardiac electrophysiology providers in Florida.
Other clinical cardiac electrophysiology in Bradenton
- Daniel FriedmanBradenton$226K
- Rajesh MalikBradenton$54K
- Usman SiddiquiWinter Park$1.2M
- Jose Osorio FilhoMiami$1.2M
- David KenigsbergFort Lauderdale$1M
- Raul WeissMiami Beach$887K
- Naushad ShaikKissimmee$691K
- Parikshit SharmaWeston$462K
- Saumil OzaJacksonville$462K
- Brian BetenskySarasota$412K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.